NASDAQ · PALI
Palisade Bio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PALI: Nov 9, 2026
Palisade Bio, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.06. The reported EPS for the same quarter last year was $-0.38.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.06 | $-0.05 | $-0.07 | 7 |
| Dec 2026 | $-0.06 | $-0.05 | $-0.08 | 7 |
| Mar 2027 | $-0.07 | $-0.05 | $-0.08 | 3 |
| Jun 2027 | $-0.07 | $-0.05 | $-0.08 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · MarketBeat · BNK Invest- RTTNews · Oct 29, 1:17 AM EDTPalisade Doses First Patient In Phase 2b Ulcerative Colitis Trial; Data Expected Q4 2027(RTTNews) – Palisade Bio, Inc. (PALI) announced Wednesday that it dosed the first patient in its global Phase 2b ASCENTRA-UC trial of once-daily oral PALI-2108 for moderately to severely active ulcerative colitis.
- RTTNews · Oct 20, 11:33 AM EDTPalisade Bio Rises 9% As PALI-2108 Shows Early Activity In Crohn's Disease(RTTNews) – Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases, presented new clinical and translational findings for its investigational drug PALI-2108 at UEG Week 2026 in Barcelona, Spain. The findings hi
- RTTNews · Oct 12, 10:34 AM EDTPalisade Bio Presents PALI-2108 Data Supporting Phase 2 Trials In Inflammatory Bowel Disease(RTTNews) – Palisade Bio Inc. (PALI), a clinical-stage biopharmaceutical company, presented new clinical and translational data for PALI-2108 in ulcerative colitis and Crohn's disease at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting.
- Fintel · Oct 9, 12:58 PM EDTRaymond James Initiates Coverage of Palisade Bio with OutperformFintel reports that on October 9, 2026, Raymond James initiated coverage of Palisade Bio (NASDAQCM:PALI) (DB:7NS0) with a Outperform recommendation.Palisade Bio, Inc. is a biopharmaceutical company based in the United States, primarily focused on the development of therapeutics t
- MarketBeat · Sep 27, 1:01 PM EDTPalisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’sPalisade Bio (NASDAQ:PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn’s disease after completing its Phase I program. Chief Executive Officer JD Finley said PALI-2108 is a once-daily oral phosphodiesterase 4, o
- RTTNews · Sep 23, 10:19 AM EDTPalisade Wins Health Canada Clearance For Phase 2 ASCENTRA-UC Study(RTTNews) – Palisade Bio (PALI) said Health Canada has cleared its Clinical Trial Application (CTA) for ASCENTRA-UC, a global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis (UC).
- RTTNews · Sep 23, 4:34 AM EDTPalisade Bio Gets FDA Clearance For PALI-2108 IND In Crohn's Disease(RTTNews) – Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company developing prodrugs for inflammatory and fibrotic diseases, said the U.S. FDA has cleared its Investigational New Drug (IND) application for PALI-2108 in moderate to severe Crohn's disease.
- RTTNews · Aug 11, 1:44 AM EDTPalisade Bio Q2 Net Loss Expands; Plans Phase 2 ASCENTRA-UC Trial Enrollment In H2 2026; Stock Down(RTTNews) – Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company, reported financial results for the second quarter ended June 30, 2026, reflecting a wider net loss and provided a business update.
- BNK Invest · Jul 7, 11:12 AM EDTTuesday 7/7 Insider Buying Report: PALIBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today
- RTTNews · Jun 29, 11:11 AM EDTFDA Clears Palisade Bio's IND For PALI-2108 In UC; Plans Phase 2 ASCENTRA-UC In H2,2026; Stock Up(RTTNews) – Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company, marked a development milestone on Monday, as the U.S. Food and Drug Administration (FDA) cleared the company's Investigational New Drug (IND) application for its lead program, PALI-2108, in patient
- Fintel · Apr 9, 8:03 PM EDTWolfe Research Initiates Coverage of Palisade Bio (PALI) with Outperform RecommendationFintel reports that on April 9, 2026, Wolfe Research initiated coverage of Palisade Bio (NasdaqCM:PALI) with a Outperform recommendation. Analyst Price Forecast Suggests 487.47% Upside
- RTTNews · Mar 31, 6:48 AM EDTPalisade Bio Reports Positive Topline Data From Phase 1b Study Of PALI-2108 In FSCD But Stock Down(RTTNews) – Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company, announced positive topline data from its Phase 1b clinical study evaluating PALI-2108 in 5 patients with Fibrostenotic Crohn's disease or FSCD.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Palisade Bio, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.